The stock jumped 21.4% on August 7. The headline number was a beat — revenue of $257.5 million, up 6.6% year-over-year, and an adjusted loss of $3.49 per share versus consensus expecting a $4.10 loss. But the beat itself doesn't explain the move. What changed investor minds was the free cash flow number and the raised full-year guidance. The rest is debt.
Claritev is a healthcare data and insights company — formerly MultiPlan, rebranded in February 2025 — that processes claims, runs independent dispute resolution under the No Surprises Act, and sells pricing-intelligence software to payers, employers, and third-party administrators. It has 1.4 million contracted providers and 750,000 payers on its network. The operating business is real and cash-generative. The balance sheet is what makes the stock a study in tension.
The operating business is finally working
Five consecutive quarters of revenue growth. That's the top-line trajectory, and 6.6% year-over-year is the fastest pace since late 2023. On a comparable basis — stripping out $5.4 million in one-time network revenue from the prior-year quarter — growth was closer to 9%.
Adjusted EBITDA, which strips out depreciation, interest, taxes, and restructuring costs to approximate operating cash generation, came in at $155.8 million, up 1.1% from $154.0 million a year ago. That's not impressive growth. But the margin compression tells the real story: 60.5% versus 63.8% in Q2 2025, a 330-basis-point slide. Revenue is growing faster than earnings because ClaritevCTEV-- is expanding into lower-margin verticals — third-party administrators and Medicare Advantage — while the legacy network segment continues to decline high single digits on a full-year basis.
The margin compression is a feature of the strategy, not a bug. Management is trading near-term EBITDA percentage points for bookings growth. H1 2026 bookings reached $74 million in annual contract value, already exceeding the full-year 2025 total of $67 million. The company targets $100 million this year, a 50% increase, with TPAs expected to contribute roughly 30% of new bookings. Claims Intelligence — the segment that benefits from the No Surprises Act — grew close to 14% in Q2, driven by arbitration outcomes that outperformed industry benchmarks by about 8 percentage points.
Quick Backtesting Tool
Bookings take two to four quarters to generate the first dollar of revenue and another four quarters to fully annualize. The $300 million pipeline, up 50% year-over-year, gives management cover to say the second-half trajectory is intact even though H2 compares against prior-year quarters that included one-time network revenue.
The cash flow inflection is what the market cared about
Here's the number that mattered most. Levered free cash flow — cash from operations minus capital expenditures and debt repayments — was $54.6 million in Q2, up 49% from $36.6 million a year ago and the strongest quarterly result in 15 quarters. Operating cash flow hit $93 million, up 51% year-over-year.
On a full-year basis, management raised free cash flow guidance from $0–$10 million to $5–$15 million. That means Claritev is now expected to end fiscal 2026 cash-flow positive, a reversal from the $12.3 million free cash flow deficit recorded in FY2025.
Why does this matter? Because free cash flow is the only metric on this company's income statement that isn't buried by debt servicing. GAAP operating income was $23.4 million in Q2. Quarterly interest expense was $100.2 million. The net loss was $59.2 million. The operating business generates enough cash to fund capex and still have $54.6 million left over. That left-over cash is what keeps the creditors paid and the equity from being wiped out entirely.
The valuation disconnect
The equity trades at 0.38 times trailing sales. Market cap is roughly $448 million. That's cheap by any healthcare-software standard.
Enterprise value tells a different story. Add the $5.1 billion in total debt (net of minimal cash on the balance sheet), and you get an enterprise value of roughly $5.10 billion, or about 14.5 times trailing EV/EBITDA and 5.4 times sales. Total equity on the balance sheet is negative — $234.4 million — because accumulated losses and debt have consumed the book value. The debt-to-equity ratio is meaningless in absolute terms; the point is that the equity holders own a tiny slice of a very large enterprise.
In our book, that's the defining feature of this name. The operating business is worth several billion dollars. The equity is worth a fraction of that because creditors stand in front of shareholders on every dollar of cash flow. The stock is a high-leverage call on execution — and the 21% single-day move shows exactly how sensitive the equity is to any change in the narrative.
The stock has been down roughly 37% year-to-date and 56% from its 52-week high of $74.07. The forward P/E of 4.07x (based on next-year profit forecasts from analysts who believe the turnaround will complete) is irrelevant for anyone who doesn't share that conviction. The trailing P/E is negative. The P/B is negative. The only valuation anchor that works here is EV/EBITDA relative to what the business will look like in two years, not today.
The raised guidance and what it implies
Management lifted full-year 2026 revenue guidance to $1.00–$1.02 billion, up from $985 million–$1.0 billion, implying 4–6% growth. Adjusted EBITDA guidance moved to $610–$620 million from $605–$615 million, with margins settling around 61%. Capital expenditures remain at $160–$170 million.
The guidance raise is modest but meaningful for two reasons. First, it marks a return to over $1 billion in annual revenue for the first time since 2022. Second, the company is guiding to full-year cash-flow positivity despite maintaining aggressive capex levels. That's a signal that operating leverage is real, even if the margin trajectory is flattening.
Q3 revenue is expected to be flat sequentially versus Q2's $257.5 million. Guidance implies a modest step-up into Q4, with management planning conservatively to protect free cash flow. The pipeline supports the trajectory, but the conversion cycle — two to four quarters from booking to first revenue dollar — means H2 bookings won't show up on the income statement until 2027 at the earliest.
Where this fits in a portfolio
Claritev belongs in a turnaround sleeve, not a growth sleeve. The factor stack shows revenue growth that's positive but modest (5.5% year-over-year), profitability that's improving in absolute dollar terms but compressing as a percentage, and cash flow that's finally turning the corner after years of structural deficit. Momentum is building — the stock is above its 50-day moving average of $28.64 with an RSI of 64.5, neither overbought nor neutral, but clearly recovering from a prolonged downtrend. The 200-day moving average sits at $30.70, and the stock just broke above it on volume.
The trade is binary. If bookings continue to convert, NSA claims volume holds, and the company delivers on the $100 million bookings target while maintaining positive free cash flow, the equity has significant room to re-rate. The enterprise is worth several billion dollars; the equity is priced as if something could go very wrong. Something already did — the stock fell 56% from its high — and that fall priced in a lot of the risk.
The counterpoint is the debt. $5.1 billion in total debt with $100 million in quarterly interest expense is not a minor footnote. If bookings slip, if NSA regulatory changes reduce claims volume, or if the macro softens and employers push back on pricing-intelligence spend, the cash flow cushion narrows fast. The company ended Q2 with $14.4 million in unrestricted cash. It has access to a revolving credit facility with $70 million drawn. Liquidity is adequate but not forgiving.
What would change the thesis on the downside? A bookings miss in Q3 or Q4, a meaningful step-down in free cash flow guidance, or any signal that NSA claims volume is structurally declining. All three would confirm that the turnaround narrative is premature.
What would confirm the upside? A full-year 2026 that hits the $100 million bookings target, delivers positive free cash flow at the mid-to-upper end of guidance, and sets up 2027 as a year where the first bookings dollars from the current pipeline start flowing through. At that point, the valuation disconnect between the operating business and the equity narrows materially.
For now, the factor stack says: revenue growth is intact, cash flow is turning, guidance is being raised, and momentum is shifting. The balance sheet says: proceed with size discipline. This is a conviction trade, not a core holding. The equity is cheap because the debt is heavy. If the operating execution holds, the cheap equity catches up. If it doesn't, the cheap equity gets cheaper. That's the trade.
CTEV closed August 7 at $32.59, up $5.75 on the session, with 330,000 shares changing hands. The previous close was $26.84. The 52-week range remains $11.50 to $74.07. The stock is 43.5% higher over the past five days but still down 23.8% year-to-date against an S&P 500 that's up 12.6% over the same period.
